The proposed US Most Favored Nation (MFN) policy is still making headlines and has already been reshaping global pricing and market access (P&MA) strategies.
Join our upcoming webinar to explore Simon-Kucher’s latest perspectives on the evolving MFN landscape, the potential implications of the US midterm election results, the developments and adaptations observed in HTA and P&MA processes across individual ex-US markets, and how pharma companies are responding to these changes.
Our experts will discuss the potential impact of these policies on global P&MA dynamics, as well as practical approaches to adapting commercial and P&MA strategies in an uncertain environment.
Participants will learn:
- The latest developments surrounding the GLOBE, GUARD, and PROSPECTIVE MFN models
- How the US midterm election results could influence the future direction, implementation, and durability of MFN policies
- Emerging strategies for launch pricing, regulatory planning, and launch sequencing
- How ex-US markets are adapting their HTA and P&MA policies in response to MFN
- Alternative access pathways, including private health insurance (PHI), out-of-pocket (OOP) payments, and foreign importation, and their associated opportunities and limitations
- How MFN fits together with the developments around the European Pharma Legislation
- Key uncertainties and potential scenarios shaping the MFN landscape in 2027, post-2029, and beyond
The webinar is free of charge.
